Company Profile

TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection. TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.

Employees

Sector

Biotechnology & Medical Research

More about the company

Real-time Euronext Paris Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-.--%	+67.53%

18-10-01	TxCell : Sangamo and TxCell announce the completion of the acquisition by Sangamo of majority of TxCell ordinary shares	PR
18-07-23	TxCell : Sangamo Therapeutics to Acquire TxCell	PR
18-07-09	TxCell : exercises in-license option to the University of British Columbia’s intellectual property rights of the HLA-A2 CAR-Treg program	PU
18-06-21	TxCell : First in vivo proof-of-concept data with CD8+ CAR-Treg presented at FOCIS 2018	PU
18-05-28	TxCell : to present its latest manufacturing process achievements at the 3rd Annual Bioprocessing of Advanced Cellular Therapies Congress	PU

18-12-03	TxCell : acquisition par Sangamo finalisée
18-11-27	TxCell : retrait obligatoire ce jeudi
18-11-26	TxCell : près de sept millions d'actions apportées à l'OPAS
18-11-23	TXCell : Sangamo Therapeutics dépasse les 90%
18-11-15	TxCell : 'la rencontre avec Sangamo était une évidence'

Manager	Title	Age	Since
Sandrine Boulet COO	Chief Operating Officer	50	-
Pierre Desreumaux PRN	Corporate Officer/Principal	-	-
Bernard Malissen PRN	Corporate Officer/Principal	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TXCELL	-.--%	-.--%	-	-	0
ARGENX SE	-1.53%	+0.78%	+72.33%	+127.47%	57.72B
WUXI APPTEC CO., LTD.	-2.45%	-7.32%	+65.23%	+83.15%	52.65B
INSMED INCORPORATED	+3.22%	+8.39%	+20.64%	+468.53%	24.46B
BIONTECH SE	-1.44%	-1.43%	-17.09%	-13.82%	23.84B
WUXI BIOLOGICS (CAYMAN) INC.	-3.05%	+3.06%	+42.36%	-5.66%	19.28B
GENMAB A/S	-0.24%	+5.11%	+38.76%	-25.95%	17.8B
PHARMAESSENTIA CORPORATION	+2.34%	+14.18%	+220.96%	+380.99%	17.29B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-6.73%	+9.90%	+36.04%	-	15.28B
EXELIXIS, INC.	-2.41%	+3.36%	+28.19%	+192.48%	14.35B
Average	-1.24%	+5.20%	+56.38%	+150.90%	26.96B
Weighted average by Cap.	-1.38%	+2.71%	+57.64%	+139.15%

TxCell Stock

Stocks

TXCL

FR0010127662

Biotechnology & Medical Research

Press Releases: TxCell

News in other languages: TxCell

Managers and Directors: TxCell

Bio Therapeutic Drugs

Company Profile